StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Tinidazol

Tinidazole

HCID 5479
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
148159-84-6
Standard-SMILES
CCS(=O)(=O)CCn1c([N+](=O)[O-])cnc1C
InChIKey
HJLSLZFTEKNLFI-UHFFFAOYSA-N
Summenformel
C8H13N3O4S
Durchschnittliche Molmasse
247,27 g/mol
Monoisotopische Masse
247,0626769

Überblick

Tinidazole is 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent. It has a role as an antiamoebic agent, an antiparasitic agent, an antiprotozoal drug and an antibacterial drug.

Namen und Bezeichner

Bevorzugter Name
Tinidazole
IUPAC
1-(2-ethylsulfonylethyl)-2-methyl-5-nitroimidazole
Lokaler Name
Tinidazol
Englischer Name
Tinidazole
Summenformel
C8H13N3O4S
Molmasse
247.27

Namen und Synonyme

tinidazole19387-91-8FasigynTrimonaseFasiginTricolam1-(2-(Ethylsulfonyl)ethyl)-2-methyl-5-nitro-1H-imidazoleSimplotanTinidazolSorquetanHaisigynTinidazolum
Weitere Namen anzeigen
TIXIAOZUO1-(2-(ethylsulfonyl)ethyl)-2-methyl-5-nitro-1h-imidazolpletibioshikcp12574
1-(2-ethylsulfonylethyl)-2-methyl-5-nitroimidazolePletilCP 12574timidazole1-[2-(Ethylsulfonyl)ethyl]-2-methyl-5-nitro-1H-imidazoleCP-125741-[2-(ethanesulfonyl)ethyl]-2-methyl-5-nitro-1H-imidazoleDTXSID4023676

Datenbank-Bezeichner

CAS
148159-84-6、19387-91-8
PubChem CID
5479
DTXSID
DTXSID4023676
ChEMBL
CHEMBL1220
ChEBI
CHEBI:63627
UNII
033KF7V46H
EC Number
243-014-4
Nikkaji
J2.752I

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
-0,4
Polarare Oberfläche (TPSA)
106 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
5
Frei drehbare Bindungen
4
Schwere Atome
16
Formalladung
0
Komplexität
345

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Antibiotics

LogP · 3 Einträge

log Kow = -0.35

0.7

-0.38

Color/FormColorless crystals from benzene
Solubility · 2 Einträge

3.03e+00 g/L

>37.1 [ug/mL] (The mean of the results at pH 7.4)

Human Drugs · 4 Einträge

Breast Feeding; Lactation; Anti-Infective Agents; Antibacterial Agents; Antiprotozoal Agents; Nitroimidazoles

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Antiamoebic and antigiardiasis medicines

Animal DrugsPharmaceuticals -> Animal Drugs -> Approved in Taiwan
Melting Point · 3 Einträge

127-128 °C

127-128 °C

127 - 128 °C

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H312 (56.8%): Harmful in contact with skin [Warning Acute toxicity, dermal]

P203, P261, P271, P280, P302+P352, P304+P340, P317, P318, P321, P362+P364, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 74 reports by companies from 7 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory InformationTinidazole: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - 1H-Imidazole, 1-[2-(ethylsulfonyl)ethyl]-2-methyl-5-nitro-: Environment tier I assessment
FDA Requirements · 1 Eintrag

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl tinidazole, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

Special ReportsManes G, Balzano A.; Tinidazole: From Protozoa to Helicobacter Pylori--The Past, Present and Future of a Nitroimidazole with Peculiarities; Expert Rev Anti Infect Ther 2 (5): 695-705 (2004)
Hazard Classes and CategoriesAcute Tox. 4 (56.8%)

Sicherheit und Schutzausrüstung

Disposal Methods

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 6 Einträge

J01XD02

P - Antiparasitic products, insecticides and repellents

J - Antiinfectives for systemic use

G - Genito urinary system and sex hormones

QG - Genito urinary system and sex hormones

QJ - Antiinfectives for systemic use

Protein BindingPlasma protein binding of tinidazole is 12%.
Pharmacodynamics · 1 Eintrag

Tinidazole is a synthetic antiprotozoal agent. Tinidazole demonstrates activity both in vitro and in clinical infections against the following protozoa: <i>Trichomonas vaginalis</i>, <i>Giardia duodenalis</i> (also termed <i>G. lamblia</i>), and <i>Entamoeba histolytica</i>. Tinidazole does not appear to have activity against most strains of vaginal lactobacilli.

Mechanism of Action · 2 Einträge

Tinidazole is a prodrug and antiprotozoal agent. The nitro group of tinidazole is reduced in <i>Trichomonas</i> by a ferredoxin-mediated electron transport system. The free nitro radical generated as a result of this reduction is believed to be responsible for the antiprotozoal activity. It is suggested that the toxic free radicals covalently bind to DNA, causing DNA damage and leading to cell death. The mechanism by which tinidazole exhibits activity against <i>Giardia</i> and <i>Entamoeba</i> species is not known, though it is probably similar.

The nitro group of tinidazole is reduced by cell extracts of Trichomonas. As a result of this reduction a free nitro radical is generated which may be responsible for the antiprotozoal activity. The mechanism by which tinidazole exhibits activity against Giardia and Entamoeba species is not known.

Biological Half-Life · 2 Einträge

The elimination half-life is 13.2±1.4 hours and the plasma half-life is 12 to 14 hours.

Elimination: 13.2 (+ or - 1.4) hours. Plasma: approximately 12 to 14 hours.

Metabolism/Metabolites · 2 Einträge

Hepatic, mainly via CYP3A4. Tinidazole, like metronidazole, is significantly metabolized in humans prior to excretion. Tinidazole is partly metabolized by oxidation, hydroxylation and conjugation. Tinidazole is the major drug-related constituent in plasma after human treatment, along with a small amount of the 2-hydroxymethyl metabolite.

Zugehörige Reaktionen

3
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 125211
HRID 125211als Produkt
Reaktionsgleichung von HRID 681391
HRID 681391als Produkt
Reaktionsgleichung von HRID 971469
HRID 971469als Produkt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
Physical Description
Solid
Collision Cross Section149.7 Ų [M+H]+ [CCS Type: TW; Method: calibrated with Waters Major Mix]

Physikochemische Eigenschaften

Schmelzpunkt
118 · 118-120C
Siedepunkt
528.4 · 528.4±30.0 °C(Predicted)
Dichte
1.4338 · 1.4338 (rough estimate)
Brechungsindex
1.632 · 1.6320 (estimate)
storage temp.
Sealed in dry,Room Temperature
Löslichkeit
Practically insoluble in water, soluble in acetone and in methylene chloride, sparingly soluble in methanol.
pka
2.3 · 2.30±0.34(Predicted)
Aggregatzustand
Solid
Farbe
Off-White to Pale Yellow
Merck
14 · 14,9447
BRN
618182 · 618182
Henry's Law Constant
1.9 · 1.9×105 mol/(m3Pa) at 25℃, HSDB (2015)
Stabilität
Stable. Incompatible with strong oxidizing agents.
Major Application
forensics and toxicologypharmaceutical (small molecule)
InChI
1S/C8H13N3O4S/c1-3-16(14,15)5-4-10-7(2)9-6-8(10)11(12)13/h6H,3-5H2,1-2H3
InChIKey
HJLSLZFTEKNLFI-UHFFFAOYSA-N
SMILES
CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O
CAS Datenbank
19387 · 19387-91-8(CAS DataBase Reference)
· 1 Eintrag

SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.

Toxikologische Informationen

Interactions · 5 Einträge

Cholestyramine may decrease oral bioavailability; separate dosing of cholestyramine and tinidazole is recommended.

Effects may be enhanced when these agents /coumarin anticoagulants/ are used concurrently with tinidazole resulting in prolongation of prothrombin time; dosage of oral anticoagulants may need to be adjusted during tinidazole therapy and up to 8 days after discontinuation.

It is recommended that these substances /ethyl alcohol, ethanol-containing preparations, propylene glycol/ not be used concurrently with tinidazole, or for 3 days following tinidazole therapy; abdominal cramps, nausea, vomiting, headache, or flushing may occur.

Concomitant administration /of intravenous phenytoin or intravenous fosphenytoin/ with tinidazole increases half life and decreases clearance of phenytoin.

For more Interactions (Complete) data for TINIDAZOLE (11 total), please visit the HSDB record page.

Hepatotoxicity · 1 Eintrag

Tinidazole is typically given for a few days only, but serum enzyme elevations have been reported with its use, and serum enzyme elevations during therapy is listed as a possible adverse event in the product label. Tinidazole is also capable of causing anaphylactic and allergic reactions including urticaria, angioedema and bronchospasm, reactions which can be associated with minor serum enzyme elevations. Tinidazole, despite considerable use worldwide, has not been linked convincingly to instances of clinically apparent liver injury with jaundice.

Environmental Fate · 3 Einträge

TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 15(SRC), determined from a log Kow of -0.35(2) and a regression-derived equation(3), indicates that tinidazole is expected to have very high mobility in soil(SRC). The estimated pKa of tinidazole is 4.7 (sp2 hybridized imidazole nitrogen)(4), indicating that this compound will exist partially as a cation in the environment under acidic conditions and cations generally have lower mobility in soil than their neutral counterparts(5). Volatilization of tinidazole from moist soil surfaces is not expected to be an important fate process(SRC) because cations do not volatilize and based on an estimated Henry's Law constant of 5.2X10-11 atm-cu m/mole(SRC), calculated using a fragment constant estimation method(6). Tinidazole is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 2.7X10-7 mm Hg(SRC), determined from a fragment constant method(7). Biodegradation data were not available(SRC, 2005).

AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 15(SRC), determined from a log Kow of -0.35(2) and a regression-derived equation(3), indicates that tinidazole is not expected to adsorb to suspended solids and sediment(SRC). The estimated pKa of tinidazole is 4.7 (sp2 hybridized imidazole nitrogen)(3), indicating that this compound will exist partially as a cation in the environment under acidic conditions and cations generally adsorb more strongly to sediment than their neutral counterparts(4). Volatilization from water surfaces is not expected(5) because cations do not volatilize and based upon an estimated Henry's Law constant of 5.2X10-11 atm-cu m/mole(SRC), developed using a fragment constant estimation method(6). According to a classification scheme(7), an estimated BCF of <1(SRC), from the measured log Kow(2) and a regression-derived equation(8), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Biodegradation data were not available(SRC, 2005).

ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), tinidazole, which has an estimated vapor pressure of 2.7X10-7 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase tinidazole may be removed from the air by wet or dry deposition(SRC). Tinidazole does not contain chromophores that absorb at wavelengths >290 nm and therefore is not expected to be susceptible to direct photolysis by sunlight(SRC).

Milk ConcentrationsTinidazole is distributed into breast milk at concentrations similar to those in serum.
Soil Adsorption/Mobility · 1 Eintrag

The Koc of tinidazole is estimated as 15(SRC), using a log Kow of -0.35(1) and a regression-derived equation(2). According to a classification scheme(3), this estimated Koc value suggests that tinidazole is expected to have very high mobility in soil. The estimated pKa of tinidazole is 4.7 (sp2 hybridized imidazole nitrogen)(4), indicating that this compound will partially exist in the cation form in the environment under acidic conditions and cations generally have lower mobility in soil than their neutral counterparts(5).

Artificial Pollution SourcesTinidazole's production and use as an antiprotozoal agent(1) may result in its release to the environment through various waste streams(SRC).
Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Tinidazole

vLess-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Environmental Bioconcentration · 1 Eintrag

An estimated BCF of <1 was calculated for tinidazole(SRC), using a log Kow of -0.35(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).

Volatilization from Water/Soil · 1 Eintrag

The Henry's Law constant for tinidazole is estimated as 5.2X10-11 atm-cu m/mole(SRC) using a fragment constant estimation method(1). The estimated pKa of tinidazole is 4.7 (sp2 hybridized imidazole nitrogen)(2), indicating that this compound will exist partially as a cation in the environment under acidic conditions. Based on this Henry's Law constant and the fact that cations do not volatilize, tinidazole is expected to be essentially nonvolatile from moist soil and water surfaces(3). Tinidazole is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 2.7X10-7 mm Hg(SRC), determined from a fragment constant method(4).

Non-Human Toxicity Excerpts · 5 Einträge

/LABORATORY ANIMALS: Chronic Exposure or Carcinogenicity/ Metronidazole, a chemically-related nitroimidazole, has been reported to be carcinogenic in mice and rats but not hamsters. In several studies metronidazole showed evidence of pulmonary, hepatic and lymphatic tumorigenesis in mice and mammary and hepatic tumors in female rats. Tinidazole carcinogenicity studies in rats, mice or hamsters have not been reported.

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Embryo-fetal developmental toxicity studies in pregnant mice indicated no embryo-fetal toxicity or malformations at the highest dose level of 2,500 mg/kg.

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Sixty-day fertility study done in male rats given doses (600 mg/kg/day) of tinidazole, resulting in reduced fertility and produced testicular histopathology. Spermatogenic effects resulted from dose levels of 300 and 600 mg/kg/day, while the no observed adverse effects dose level was 100 mg/kg/day. These effects are characteristic of agents in the 5-nitroimidazole class.

/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ In a study with pregnant rats a slightly higher incidence of fetal mortality was observed at a maternal dose of 500 mg/kg. No biologically relevant neonatal developmental effects were observed in rat neonates following maternal doses as high as 600 mg/kg.

/GENOTOXICITY/ Tinidazole was found to be mutagenic in the TA100, S. typhimurium testere strain both with and without the metabolic activation system and was not mutagenic in the TA98 strain. However mutagenicity results were mixed both positive and negative in the TA1535, 1537, and 1538 strains. Tinidazole was also positive in a tester strain of Klebsiella pneumonia and positive for in vivo genotoxicity in the mouse micronucleus assay. Tinidazole was negative for mutagenicity in a mammalian cell culture system with Chinese hamster lung V79 cells and negative for genotoxicity in the Chinese hamster ovary sister chromatid exchange assay.

Environmental Abiotic Degradation · 1 Eintrag

Tinidazole is not expected to undergo hydrolysis in the environment due to the lack of functional groups that hydrolyze under environmental conditions(1). Tinidazole does not contain chromophores that absorb at wavelengths >290 nm and therefore is not expected to be susceptible to direct photolysis by sunlight(SRC).

Probable Routes of Human Exposure · 1 Eintrag

Occupational exposure to tinidazole may occur through inhalation and dermal contact with this compound at workplaces where tinidazole is produced or used. Exposure to tinidazole among the general population may be limited to those administered this substance as a drug. (SRC)

Regulatorische Informationen

FDA Requirements · 1 Eintrag

The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl tinidazole, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

Sicherheitsdaten

wgk
3
hs_code
2933290000
RTECS-Nr.
NI6255000
risk_code
20/21/22-40
Toxizität
LD50 in mice (mg/kg): >3600 orally; >2000 i.p. (Miller)
hazard_code
Xn
safety_code
26-36
Speicherklasse
11 - Combustible Solids
Giftige Stoffe Daten
19387-91-8(Hazardous Substances Data)
Hazard Classifications
Acute Tox. 4 DermalAcute Tox. 4 InhalationCarc. 2Muta. 2

Tinidazole, like metronidazole, is significantly metabolized in humans prior to excretion. Tinidazole is partly metabolized by oxidation, hydroxylation and conjugation. Tinidazole is the major drug-related constituent in plasma after human treatment, along with a small amount of the 2-hydroxymethyl metabolite. Tinidazole is biotransformed mainly by CYP3A4. In an in vitro metabolic drug interaction study, tinidazole concentrations of up to 75 ug/mL did not inhibit the enzyme activities of CYP1A2, CYP2B6, CYP2C9, CYP2D6, CYP2E1 and CYP3A4.

FDA Pharmacological Classification · 6 Einträge

033KF7V46H

TINIDAZOLE

Established Pharmacologic Class [EPC] - Nitroimidazole Antimicrobial

Chemical Structure [CS] - Nitroimidazoles

Tinidazole is a Nitroimidazole Antimicrobial.

TINIDAZOLE

MeSH Pharmacological Classification · 3 Einträge

Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases.

Agents used to treat trichomonas infections.

Substances that inhibit the growth or reproduction of BACTERIA.

Absorption, Distribution and Excretion · 6 Einträge

Rapidly and completely absorbed under fasting conditions. Administration with food results in a delay in Tmax of approximately 2 hours and a decline in Cmax of approximately 10% and an AUC of 901.6 ± 126.5 mcg hr/mL.

Tinidazole crosses the placental barrier and is secreted in breast milk. Tinidazole is excreted by the liver and the kidneys. Tinidazole is excreted in the urine mainly as unchanged drug (approximately 20-25% of the administered dose). Approximately 12% of the drug is excreted in the feces.

50 L

Tinidazole is distributed into virtually all tissues and body fluids. Tinidazole also crosses the blood-brain barrier, placental barrier and is distributed into breast milk. Volume of distribution (VolD): about 50 L.

Under fasted conditions tinidazole is rapidly and completely absorbed. Administration with food resulted in a delay in Tmax of approximately 2 hours and a decline in Cmax of approximately 10% and an AUC of 901.6 + or - 126.5 ug hr/mL.

Time to peak concentration: 1.6 (+ or - 0.7 hours)

Cellular LocationsCytoplasm

Verwendung und Herstellung

Uses · 3 Einträge

MEDICATION

Antitrichomonal Agents

Antiprotozoal and antibacterial activity

Methods of ManufacturingSynthesis: heating 2-methyl-5-nitroimidazole with 2-ethylsulfonylethyl-4-toluenesulfonate for 4 h
Formulations/PreparationsOral: Tablets, film-coated: 250 mg Tindamax (scored), (Presutti); 500 mg Tindamax (scored), (Presutti).
Use ClassificationPharmaceuticals -> Animal Drugs -> Approved in Taiwan

Anwendungen

VerwendenAntiprotozoal (Trichomonas, Giardia); antiamebic; antibacterial.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Tosylchlorid2-(ETHYLSULFONYL)ETHANOL2-Methyl-5-nitroimidazole